Dealing with the high-risk potential of COVID-19 cross-infection in dental practice

Heribertus Dedy Kusuma Yulianto; Nunuk Purwanti; Trianna Wahyu Utami; Anne Handrini Dewi; Dyah Listyarifah; Intan Ruspita; Asikin Nur; Heni Susilowati

doi:10.22146/majkedgiind.56588

Dealing with the high-risk potential of COVID-19 cross-infection in dental practice

https://doi.org/10.22146/majkedgiind.56588

Heribertus Dedy Kusuma Yulianto⁽¹⁾, Nunuk Purwanti⁽²⁾, Trianna Wahyu Utami⁽³⁾, Anne Handrini Dewi⁽⁴⁾, Dyah Listyarifah⁽⁵⁾, Intan Ruspita⁽⁶⁾, Asikin Nur⁽⁷⁾, Heni Susilowati^(8*)

(1) Department of Dental Biomedical Sciences, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta Integrated Research Laboratory, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta
(2) Department of Dental Biomedical Sciences, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta Integrated Research Laboratory, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta
(3) Department of Dental Biomedical Sciences, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta Integrated Research Laboratory, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta
(4) Department of Dental Biomedical Sciences, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta Integrated Research Laboratory, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta
(5) Department of Dental Biomedical Sciences, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta Integrated Research Laboratory, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta
(6) Department of Prosthodontics, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta Integrated Research Laboratory, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta
(7) Department of Dental Biomedical Sciences, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta Integrated Research Laboratory, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta
(8) Department of Oral Biology, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta Integrated Research Laboratory, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author

Abstract

The World Health Organization reported that the SARS-CoV-2 virus has infected more than 5 million people around the world. Dental care providers and health care professionals need to be aware of the high-risk potential of crossinfection since the routes of virus transmission commonly happen through droplets and aerosols. This review aimed at collecting essential knowledge about the COVID-19 needed by dental practitioners. The review focused on the oral involvement in COVID-19, the role of oral transmission as the high-risk potential of cross-infection and recommended strategies to minimize the risk of cross-infection in dental practice. We searched all the published clinical features from PubMed, Google Scholar, Scopus and hand searched library online databases, from January 2015 until May 2020. Keywords used were “COVID-19”, “Dentistry”, “Dental protection”, “Cross-contamination”, “Aerosol and non aerosol”, and ”Povidone-iodine” with their combinations. We identified 52 articles to review after the initial selection with inclusion and exclusion criteria. Results showed use of topical applications of povidine-iodine and viricidal mouthwash could significantly reduce the high-risk of cross-infection from dentistry patients who are asymptomatic with COVID-19 infection. Further safeguards include suspending all non-emergency procedures temporarily and closely screening patients for symptoms which may be suspected to be COVID-19 infection.

Keywords

COVID-19 cross-infection; emergency dental; oral transmission; povidone-iodine; systemic manifestation

Full Text:

PDF

References

1. Gugus Tugas Percepatan Penanganan COVID-19. Data sebaran. https://covid19.
go.id/. Accessed May 27, 2020.

2. Kemenkes. Pedoman pencegahan dan pengendalian corona virus disease
(COVID-19).; 2020. Diunduh dari: https://infeksiemerging.kemkes.go.id/downloads/?dl_cat=0&dl_search=pedoman+dan+pencegahan+covid#.Xs1qXGgzbIU pada 27 May 2020.

3. Dar Odeh N, Babkair H, Abu-Hammad S, Borzangy S, Abu-Hammad A, Abu-Hammad O. COVID-19: Present and future challenges for dental practice. Int J Environ Res Public Health. 2020; 17(9): 3151. doi: 10.3390/ijerph17093151

4. Lo Giudice R. The severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) in dentistry. Management of biological risk in dental practice. Int J Environ Res Public Health. 2020; 17(9): 3067. doi: 10.3390/ijerph17093067

5. Dawood AA. Mutated COVID-19 may foretell a great risk for mankind in the future. New Microbes New Infect. 2020; 35: 100673.
doi: 10.1016/j.nmni.2020.100673

6. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferonstimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020; 181(5): 1016-1035. e19. doi: 10.1016/j.cell.2020.04.035

7. Flor. J. Surviving COVID-19 pneumonia at home: COVID case #1906. Philipp J
Otolaryngol Head Neck Surg. 2020; 35(1): 78-79. doi: 10.32412/pjohns.v35i1.1259

8. Actor JK. Humoral Immunity. In: Elsevier’s Integrated Review Immunology and
Microbiology. Elsevier; 2012: 17-24. doi: 10.1016/B978-0-323-07447-6.00003-X

9. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020; 63(3): 457-460. doi: 10.1007/s11427-020-1637-5

10. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity,
inflammation and intervention. Nat Rev Immunol. 2020; 20(6): 363-374.
doi: 10.1038/s41577-020-0311-8

11. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM‐IgG
combined antibody test for SARS‐CoV‐2 infection diagnosis. J Med Virol. 2020: 1-7.
doi: 10.1002/jmv.25727

12. Racine R, Winslow GM. IgM in microbial infections: taken for granted? Immunol Lett. 2009; 125(2): 79-85. doi: 10.1016/j.imlet.2009.06.003

13. Shen C, Zhang M, Chen Y, et al. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. Theranostics. 2019; 9(1): 210-231. doi: 10.7150/thno.28434

14. Becerra-Flores M, Cardozo T. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. Int J Clin Pract. 2020. doi: 10.1111/ijcp.13525

15. World Health Association (WHO). Coronavirus disease 2019 (covid-19) situation report – 73.; 2020. https://www.who.int/docs/default-source/coronavirus/situationreports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_6. Accessed May 28, 2020.

16. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020; 215: 108427. doi: 10.1016/j.clim.2020.108427

17. Butowt R, Bilinska K. SARS-CoV-2: Olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020; 11(9): 1200-1203. doi: 10.1021/acschemneuro.0c00172

18. Qian Z, Travanty EA, Oko L, et al. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome–coronavirus. Am J Respir Cell Mol Biol. 2013; 48(6): 742-748. doi: 10.1165/rcmb.2012-0339OC

19. Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020; 12(4): 372. doi: 10.3390/v12040372

20. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020; 14(2): 185-192. doi: 10.1007/s11684-020-0754-0

21. Li J, Fan J-G. Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol. 2020; 8(1): 1-5. doi: 10.14218/JCTH.2020.00019

22. Das G, Mukherjee N, Ghosh S. Neurological insights of COVID-19 pandemic. ACS Chem Neurosci. 2020; 11(9): 1206-1209. doi: 10.1021/acschemneuro.0c00201

23. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020. doi: 10.1016/j.jocn.2020.05.017

24. Akhmerov A, Marbán E. COVID-19 and the heart. Circ Res. 2020; 126(10): 1443-1455. doi: 10.1161/CIRCRESAHA.120.317055

25. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. doi: 10.1001/jamacardio.2020.1096

26. Kang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations in COVID -19. Heart. 2020: heartjnl-2020-317056.
doi: 10.1136/heartjnl-2020-317056

27. Carreras‐Presas CM, Sánchez JA, López‐Sánchez AF, Jané‐Salas E, Pérez MLS.
Oral vesiculobullous lesions associated with SARS‐CoV‐2 infection. Oral Dis. 2020.
doi: 10.1111/odi.13382

28. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020; 12(1): 8. doi: 10.1038/s41368-020-0074-x

29. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020; 12(1): 1-6. doi: 10.1038/s41368-020-0075-9

30. Lange C, Wolf J, Auw-Haedrich C, et al. Expression of the COVID-19 receptor ACE2 in the human conjunctiva. J Med Virol. 2020. doi: 10.1002/jmv.25981

31. Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM. Coronavirus Disease 19 (COVID-19): implications for clinical dental care. J Endod. 2020; 46(5): 584-595.
doi: 10.1016/j.joen.2020.03.008

32. Gerberding JL, Director David Fleming MW, Snider DE, et al. Morbidity and mortality weekly report guideline for hand hygiene in health-care settings recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA hand hygiene. Task Force Centers for Disease
Control and Prevention. 2002; 51.

33. Centers for Disease Control and Prevention (CDC). Infection control: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). https://www.cdc.gov/coronavirus/ 2019-ncov/hcp/infection-control-recommendations.html. Accessed May 29, 2020.

34. Centers for Disease Control and Prevention (CDC). Social Distancing, Quarantine, and Isolation. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/socialdistancing.html. Accessed May 29, 2020.

35. Centers for Disease Control and Prevention (CDC). Sequence for putting on personal protective equipment (PPE). https://www.cdc.gov/hai/pdfs/ppe/ppe-sequence.pdf. Accessed May 29, 2020.

36. Centers for Disease Control and Prevention (CDC). Interim Guidance: Healthcare Professionals 2019-nCoV | CDC. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinicalcriteria.html. Accessed May 29, 2020.

37. Ge Z, Yang L, Xia J, Fu X, Zhang Y. Possible aerosol transmission of COVID-19 and special precautions in dentistry. J Zhejiang Univ B. 2020; 21(5): 361-368.
doi: 10.1631/jzus.B2010010

38. Babu B, Gupta S, Sahni V. Aerosol box for dentistry. Br Dent J. 2020; 228(9): 660. doi: 10.1038/s41415-020-1598-3

39. American Dental Association (ADA). Dental unit water lines. https://success.ada.org/en/practice-management/guidelines-for-practicesuccess/
gps-managing-regulatory/04_dentalunit-water-lines. Accessed June 5, 2020.

40. Harrel SK, Molinari J. Aerosols and splatter in dentistry. J Am Dent Assoc. 2004; 135(4): 429-437. doi: 10.14219/jada.archive.2004.0207

41. FDI World Dental Federation. COVID-19 Outbreak: Guidance for Oral Pealth
professionals. https://www.fdiworlddental.org/covid-19-outbreak-guidance-for-oral-healthprofessionals. Accessed May 29, 2020.

42. American Dental Association (ADA). Coronavirus (COVID-19) Center for Dentists. https://success.ada.org/en/-practice-management/patients infectious-diseases-2019-novel coronavirus?utm_source=jadaorg&utm medium=cov19page&utm_content=cv-mvresourcecenter&utm_campaign=covid-19. Accessed May 29, 2020.

43. World Health Association (WHO). Infection Prevention and Control. https://www.who.int/emergencies/diseases/novel-coronavirus-
2019/technical-guidance/infection-prevention-andcontrol. Accessed May 29, 2020.

44. Scottish Dental Clinical Effectiveness Programme (SDCEP). Management of
acute dental problems during COVID-19 pandemic. www.sdcep.org.uk. Accessed May 29, 2020.

45. Mady LJ, Kubik MW, Baddour K, Snyderman CH, Rowan NR. Consideration of povidoneiodine as a public health intervention for COVID-19: Utilization as “Personal Protective Equipment” for frontline providers exposed in high-risk head and neck and skull base oncology care. Oral Oncol. 2020; 105: 104724.
doi:10.1016/j.oraloncology.2020.104724

46. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther. 2018; 7(2): 249-259. doi: 10.1007/s40121-018-0200-7

47. Challacombe SJ, Kirk-Bayley J, Sunkaraneni VS, Combes J. Povidone iodine. Br Dent J. 2020; 228(9): 656-657. doi: 10.1038/s41415-020-1589-4

48. Pattanshetty S, Narayana A, Radhakrishnan R. Povidone‐iodine gargle as a prophylactic intervention to interrupt the transmission of SARS‐CoV‐2. Oral Dis. 2020. doi: 10.1111/odi.13378

49. Parhar HS, Tasche K, Brody RM, et al. Topical preparations to reduce SARS‐CoV‐2 aerosolization in head and neck mucosal surgery. Head Neck. 2020; 42(6): 1268-1272. doi: 10.1002/hed.26200

50. HalodineTM nasal and oral antiseptics show rapid antiviral activity against SARS-CoV-2 (COVID-19). https://www.prnewswire.com/news-releases/halodine-nasal-and-oralantiseptics-show-rapid-antiviral-activityagainst-sars-cov-2--covid-19-301059003. html. Accessed May 29, 2020.

51. Müller G, Kramer A. Comparative study of in vitro cytotoxicity of povidone-iodine in solution, in ointment or in a liposomal formulation (Repithel®) and selected antiseptics. Dermatology. 2006; 212(1): 91-93. doi: 10.1159/000090102

52. Kim JH, Rimmer J, Mrad N, Ahmadzada S, Harvey RJ. Betadine has a ciliotoxic effect on ciliated human respiratory cells. J Laryngol Otol. 2015; 129(S1): S45-S50.
doi: 10.1017/S0022215114002746

DOI: https://doi.org/10.22146/majkedgiind.56588